P&G's Softest Quarter Lands Mid-Year: Flat Organic Sales Put the Entire H2 Reacceleration Story on the Clock

Results vs. Consensus

Year-over-year comparison

Sequential comparison (vs. Q1 FY26)

Assessment

Revenue: The miss is small in dollars but large in signal. Organic sales going to zero, from +2% a quarter ago, is the number that matters, because P&G is a company whose entire equity story rests on 2–4% organic growth compounded with margin expansion and buyback. Management attributes most of the softness to a demanding base period (last year's Q2 was inflated by port-strike and hurricane pantry-loading, concentrated in US family, feminine, and baby care), and the math is real: organic sales excluding Family Care were +1%, and the balance of the company outside the US grew nearly 3%. But a base-period explanation only carries the story if the "clean" quarters that follow actually reaccelerate.

Margins: Core gross margin fell 50 bps and core operating margin 70 bps despite 270 bps of productivity, because the company chose to reinvest and because mix (120 bps drag), product reinvestment (60 bps), and tariffs (60 bps) more than absorbed the productivity and pricing benefits. This is a deliberate posture rather than a loss of cost control: management is funding the innovation and demand-creation it believes will drive the H2 turn. The risk is that the reinvestment is being spent into a category whose volume is not responding.

EPS: Core EPS was flat and currency-neutral core EPS was down 2%, so there is no underlying earnings growth in the quarter once you strip FX. The GAAP line ($1.78, -5%) was dragged by higher restructuring charges, which is also why the all-in GAAP EPS guide came down. The quality tell is that P&G is holding EPS flat with productivity and share count rather than growing it with volume, which is exactly the profile you would expect at the trough of a soft patch.

Segment Performance

Beauty

Beauty was the standout for a second straight quarter, with organic sales up 4% and the only positive volume print (+3%) in the portfolio. Hair Care grew mid-single digits on innovation-led pricing in Latin America and Europe, Personal Care grew mid-single digits on North American volume and pricing, and Skin Care was up low singles on premium mix in Greater China, where SK-II and Olay premiumization are working. This is the part of P&G behaving the way the whole company is supposed to: superior product, premium mix, and volume all moving together.

"Greater China organic sales grew 3%, another quarter of growth in what remains a challenging consumer environment. Pampers and SK-II led the growth, each up mid-teens or more." — Andre Schulten, CFO

Assessment: Beauty is the proof-of-concept for the reinvention thesis; the question is whether the same playbook (superiority, premium innovation, sharper media) transfers to the higher-volume, more value-pressured US categories where P&G is actually losing share.

Health Care

Health Care organic sales rose 3% on pricing, though volume slipped 1%. The division (Oral-B, Vicks, Pepto-Bismol) is holding value but not yet driving unit demand, consistent with the company-wide theme that usage and household penetration are flat to slow.

Assessment: Steady and defensible, but pricing-led growth with negative volume is not the composition management says it wants for the long term. Watch for whether personal health care can convert its innovation pipeline into volume as comparisons ease.

Grooming

Grooming was the quarter's clearest disappointment on the margin line: organic sales decelerated to flat, volume turned negative, and segment margin contracted roughly 300 bps. Management framed the profit weakness as an arithmetic outcome of top-line softness in a high-margin business where superiority investment is not being cut, plus initiative-phasing effects across Braun and male and female grooming.

"The margin component and the bottom line component is an outcome of the top line. It's obviously a high-margin business. And so if the volume's slowing, that translates into the bottom line slowing, specifically since we don't curtail the investment in the business." — Andre Schulten, CFO

Assessment: Grooming is high-incremental-margin, so it swings profit disproportionately. The pointed-to upside (Venus, appliances, US shelf reset, CY26 innovation) is credible but back-half weighted, which fits the broader "trust the H2" ask.

Fabric & Home Care

P&G's largest segment posted flat organic sales and flat volume, weighed by the base-period trade-inventory lap in US laundry and family-adjacent categories. The forward story is the Tide "boosted" liquid relaunch, described as the biggest laundry-liquid upgrade in 20 years and now in full distribution as of December, plus the Tide Evo national expansion coming in the back half.

Assessment: This is where the H2 case is most testable, because Fabric & Home Care is big enough to move the company. The Tide relaunch is exactly the "stronger core" innovation management is betting on; it needs to convert into volume, not just shelf presence.

Baby, Feminine & Family Care

The weak link: net sales -3%, organic -4%, volume -5%, and net earnings -9%. Family Care (Bounty, Charmin, Puffs) fell roughly 10%, almost entirely because last year's Q2 was inflated by hurricane- and port-strike-driven pantry loading. Encouragingly, management said Baby Care returned to global share growth on the most recent reading and that Family Care would turn to growth (and even share growth) in January as the lap clears.

"Family Care, for example, will see strong growth in January, even turning into share growth now. And we expect similar dynamics to happen across Baby and Fem. Baby at a global level is actually growing share." — Andre Schulten, CFO

Assessment: The optical decline is largely a comp artifact and should reverse mechanically in H2. The genuine watch item is diapers, where private-label and small-brand competition is real; the "mid-tier proposition" work on Luvs and Baby Dry is a two-phase effort with phase two still to come.

Key Topics & Management Commentary

Overall Management Tone: Confident and forward-leaning, bordering on insistent. Management repeatedly characterized Q2 as the pre-planned trough and pivoted almost every answer toward the second half and a longer-horizon "reinvention," while being unusually candid that the US needs share recovery and that the volume/usage problem is not a quick fix. The posture was assured on productivity and cash, more hopeful than proven on the top-line inflection, and least convincing when pressed to quantify the timing and size of the US turn.

1. The "softest quarter" framing and the H2 reacceleration bet

The single organizing idea of the call was that Q2 was expected to be the low point and that growth reaccelerates from here. Management grounded the case in two legs: the roll-off of US base-period inventory headwinds, and the transfer of an ex-US playbook (already producing 3%+ growth outside the US) into the US market.

"We've now completed what we fully expected will be the softest quarter of the fiscal year. We have strong innovation and productivity plans for the back half of the year... We are fully activated. It's working. So we move with confidence into half two of the fiscal year." — Andre Schulten, CFO

Assessment: The base-period math is verifiable and supportive, but "it's working" is asserted, not yet evidenced in US organic sales. This is the crux of the investment debate for the next two quarters.

2. North America: real share loss, not just a comp

North America organic fell 2%, with volume down three points including roughly two points of base-period inventory headwind. Management did not hide behind the comp: it acknowledged a genuine share component and set the bar at exiting the year with US share momentum.

"I don't want to gloss over the fact that we have work to do to recover share... our objective is really to leave the fiscal year with share momentum in the US and at a global level." — Andre Schulten, CFO

Assessment: Candor is welcome, but "exit the year with momentum" is a modest ambition that implies the share bleed continues near-term. This is the bear case's strongest foothold.

3. The "reinvention" of P&G under a new CEO

In his first full fiscal year as CEO, Shailesh Jejurikar used the prepared remarks to frame a "next phase of constructive disruption": integrating a petabyte-scale data lake, AI/GenAI in molecular discovery and media creation, programmatic shelf tools, and Supply Chain 3.0 into a closed consumer loop. He argued the heavy platform investment is largely already spent and the task now is integration.

"We are inventing the CPG company of the future... It took years to build the underlying platforms and capabilities and it will take some time to fully integrate and activate these assets across the company." — Shailesh Jejurikar, CEO

Assessment: Strategically coherent and appropriately ambitious, but deliberately vague on financial quantification. The CAGNY conference (February) and a later Investor Day are the venues where this needs to become measurable; until then it is narrative.

4. Innovation pipeline: "stronger core, bigger more"

The concrete evidence behind the H2 story is a stacked innovation calendar: the Tide liquid relaunch (biggest upgrade in 20 years), Tide Evo national expansion, Olay jars and treatments with new architecture, Pampers Prestige (China silk), and Downy Intense (Mexico). The organizing philosophy is to concentrate behind a "stronger core" and a few "bigger more" transformational launches rather than proliferating SKUs.

"Adjust how we innovate with much more emphasis on a strong core and a bigger mold, and then ensure we're delivering really good consumer value." — Shailesh Jejurikar, CEO

Assessment: This is the right response to a fragmented-attention retail world and the early ex-US wins (China baby care, Mexico Downy, Brazil hair) are encouraging proof points. The open question is US velocity.

5. Value, pricing, and the volume problem

Management was explicit that future growth must come from users and usage rather than price, after five years of price-led growth through the inflation cycle. The chosen lever is improving value by improving product performance, largely without raising price, rather than deep discounting.

"A lot of the growth in the past few years has been price-driven... the opportunity for us now is to improve the value proposition for consumers... without raising the price so we can make the proposition attractive to more households." — Andre Schulten, CFO

Assessment: Strategically sound and margin-friendly if it works, but management conceded volume reacceleration "will take time" and "won't come quickly," which is a tension with the H2 acceleration promise.

6. Tariffs and the cost stack

Guidance continues to embed roughly $500M before-tax (about $400M after-tax) of tariff costs, with commodities roughly flat year-over-year and an approximately $200M after-tax FX tailwind. Below the operating line, modestly higher interest and a 20–21% core tax rate add about a $250M after-tax (~19 cents) headwind.

Assessment: The cost stack is a known, quantified drag that is already in the numbers rather than an emerging surprise. Tariffs remain the swing factor investors cannot model precisely, but management indicated the peak headwind may have passed.

7. Productivity as the fuel

Productivity delivered 270 bps in the quarter and management expressed high confidence in the productivity pipeline over the next two to three years, tying it to the two-year restructuring program. The framing was "productivity as fuel for growth, growth as fuel for EPS."

"I feel very good about... our ability to continue to drive productivity at the level we need to deliver investment and a reasonable EPS outcome. The extent of that progress will not depend on our ability to deliver productivity... It will entirely depend on our ability to stimulate top-line growth." — Andre Schulten, CFO

Assessment: This is the most bankable part of the story and the reason EPS can hold flat through a soft top line. It also frames the whole debate correctly: the constraint is demand, not cost.

8. Portfolio and capital allocation

Asked whether the portfolio is still right after a decade, the CEO reaffirmed the focus on daily-use, performance-driven categories, described a "day-one loop" of continuous portfolio review (the genesis of the June restructuring and market exits such as Argentina), and repeated that health and beauty are the two areas where P&G still wants to build a stronger presence.

Assessment: A soft signal that bolt-on M&A in health/beauty remains on the table, funded by a business returning ~$15B a year to holders. No imminent action was implied.

Guidance & Outlook

The headline is that management held the two ranges the market values most (organic sales and core EPS) while trimming only the GAAP line for higher non-core restructuring charges. Embedded in the outlook: ~$500M pretax tariffs, commodities roughly flat, a ~$200M after-tax FX tailwind, a ~$250M after-tax below-the-line headwind, and a 30–50 bps organic headwind from restructuring-related product and market exits. Capex steps up to 4–5% of sales as the company adds capacity in several categories.

Implied H2 ramp: With H1 organic tracking at roughly +1% (Q1 +2%, Q2 flat), simply reaching the low end of the full-year "in-line" outlook requires H2 organic to hold around +1–2%, and reaching the midpoint (~+2%) requires H2 to run closer to +3%. Management's own framing is a return to "the lower half of our long-term growth algorithm" as the company exits FY26.

Street at: Consensus sits toward the lower half of the core-EPS range and near ~2% organic for the year, so the guide is credible but leaves little room for another soft quarter. Q3 organic is the validation checkpoint.

Guidance style: Characteristically conservative and wide. P&G has beaten or matched EPS consensus in each of the last four quarters, and the deliberately broad ranges reflect genuinely low visibility on the pace of the US recovery and on management's own conviction to reinvest.

Analyst Q&A Highlights

What underpins the confidence in H2 acceleration

The dominant line of questioning on the call was whether the promised second-half improvement is real fundamental acceleration or merely easier comparisons. Management leaned on both, but weighted the answer toward the ex-US momentum already in the numbers and the transfer of that playbook into the US.

Q: "What gives you confidence in the near-term acceleration that you mentioned a couple of times? And to what degree is that about comparisons and base period dynamic versus real fundamental improvement and acceleration?"
— Lauren Lieberman, Barclays

A: "The first positive element of quarter two results is the strength of the business outside of the US... There's real underlying acceleration in the business outside of the US that is grounded in interventions we've made... That same playbook is being executed in the US... if we don't see any one-timers anymore in terms of base period headwinds, that will translate into stronger growth."
— Andre Schulten, CFO

Assessment: The comp roll-off is verifiable and low-risk; the playbook-transfer claim is the leap of faith. Management answered honestly that a meaningful chunk of H2 improvement is simply the absence of last year's inventory distortion, which is a lower-quality driver than genuine share recovery.

Underlying US category growth

A recurring effort to pin down the true run-rate of US category growth produced the quarter's most useful number, and a candid admission that P&G is currently growing below its market in the US.

Q: "I was trying to just pin down what you're expecting in terms of category growth for the back half of the year... whether that's the right runway or whether the guidance expects to get back to 2% to 3%."
— Peter Grom, UBS

A: "Our base expectation is 2% category growth in the back half. That's what we know and that's what we're planning on... I would not expect any significant inventory build in the second half... a slight headwind from inventory is probably adequate to assume."
— Andre Schulten, CFO

Assessment: A 2% US category-growth assumption, against which P&G ran -2% organic this quarter, quantifies the share gap the company must close just to grow in line with its market. It also caps the realistic upside: this is a low-single-digit market, not a reacceleration to mid-single digits.

The cost of the reinvention

Investors probed whether the strategic reinvention implies a new wave of investment or margin drag if the top-line turn is slow to arrive. Management pushed back firmly, arguing the heavy capability spend is already sunk.

Q: "Can you give us a sense of the sort of cost of this progress... the balance between the restructuring and some of the savings that that's going to allow for, relative to what you feel is going to be needed... if you really want to stimulate top line over the next twelve to eighteen months?"
— Chris Carey, Wells Fargo

A: "Many of the investments have been made over the last decade... The investment to activate the technology... won't be significant. It's an investment in scaling... So I wouldn't look at a cliff of investment that comes with this."
— Andre Schulten, CFO

Assessment: Reassuring on capital intensity and consistent with the "no margin cliff" message. The subtle tell is management's refusal to discuss return-to-algorithm timing ("let us get through the next two quarters"), which is a soft acknowledgment that near-term visibility is limited.

Grooming's margin contraction

The sharp deceleration and ~300 bps margin contraction in the high-margin Grooming segment drew direct scrutiny.

Q: "Organic sales were flat in the quarter, which was a pretty big deceleration versus last quarter with volumes inflecting negative and margins contracting nearly 300 bps. Could you provide more color on what drove the weakness on volumes?"
— Bonnie Herzog, Goldman Sachs

A: "The margin component and the bottom line component is an outcome of the top line. It's obviously a high-margin business... The timing of the grooming business is heavily related to initiative timing... On the second half, like other business, we expect modest acceleration in grooming, related mostly to the US."
— Andre Schulten, CFO

Assessment: An honest "it's operating deleverage plus initiative phasing" answer rather than a demand-collapse narrative. But Grooming's incremental-margin sensitivity means it will keep swinging profit until volume turns, so it is a segment to watch closely in Q3.

Promotion intensity and the discounting question

Skeptics pointed to data showing P&G's percentage of products sold on promotion is running 200–300 bps higher, questioning whether the company is quietly leaning on price to move volume.

Q: "The percent of products sold on promotion at P&G is substantially higher by about 200, 300 basis points. Do you think this data accurately represents your approach in market? Because it would indicate there is more need to move volume."
— Robert Moskow, TD Cowen

A: "Our promotion volume is increasing and probably will increase in the second half as we execute the innovation... Not all of those promotions come with deep price discounting. In many cases, they don't. But they show up in the promotion line... I don't see a reason why the categories will not move back to pre-COVID levels of promotion, which are around 30%."
— Andre Schulten, CFO

Assessment: A credible distinction between trial-driving display promotion and margin-eroding price discounting, but a partial concession that promotional intensity is rising. If the "stronger propositions" do not lift promotion elasticity as claimed, this becomes a margin risk.

Volume, usage, and household penetration

A pointed question on whether real in-home usage is deteriorating produced the most important structural admission of the call.

Q: "To the extent you're able to calculate what actual usage is in the households, has that trended off as we got into the front half of this fiscal year?"
— Kaumil Gajrawala, Jefferies

A: "Usage volume growth is slow to honestly flat if you look at the front half of the year, even in the last quarter, both in the US and in Europe. So reaccelerating household penetration, reaccelerating user growth is a big part of what we're focusing on."
— Andre Schulten, CFO

Assessment: This is the quarter's most consequential disclosure. Flat usage across the two most profitable regions is the real headwind behind stalled organic growth, and it is not something a single innovation cycle fixes quickly. It reframes the H2 story from "recovery" to "stabilization plus comp relief."

Portfolio review and M&A appetite

A step-back question on whether the portfolio still fits, more than a decade after the last major review, elicited a reaffirmation of the daily-use focus and a repeated interest in health and beauty.

Q: "Are you generally pleased with the current portfolio? Is P&G still in the right segments... or do you see it possible certain businesses may make less sense today than in years past?"
— Kevin Grundy, BNP Paribas

A: "We play in daily use categories where performance matters... We continue to look at where we can build greater strength, and we've always talked about the fact that health and beauty are two areas where we have still opportunity to build a stronger presence, and we continue to look at opportunities which come our way there."
— Shailesh Jejurikar, CEO

Assessment: A standing, low-urgency signal that bolt-on M&A in health/beauty remains a lever. Nothing imminent, but worth tracking given the cash-generative balance sheet and the strategic emphasis on those two segments.

What They're NOT Saying

1. The organic-growth streak went unmentioned. Just a quarter ago management touted "40 consecutive quarters of organic sales growth." With Q2 organic landing flat, that milestone was conspicuously absent from the prepared remarks, an implicit acknowledgment that the streak either paused or barely survived on rounding.
2. No H2 margin guidance. Asked directly, management declined to guide second-half margins, calling margin "an outcome" of investment choices. That flexibility is honest, but it also means the market cannot model the trade-off between the promised top-line acceleration and the reinvestment required to achieve it.
3. Return-to-algorithm timing was deferred. Management explicitly asked investors to "let us get through the next two quarters" before discussing when P&G gets back to its 3–5% long-term growth algorithm, signaling low conviction on the pace of recovery.
4. Quantifying the US share gap. Management acknowledged share loss and set a goal of exiting the year with momentum, but did not size the current US share deficit or commit to a quarter in which US organic turns positive.
5. The dollar size of the reinvention payoff. The "different S-curve" and "CPG company of the future" language came with no financial framing, deferred to CAGNY and a later Investor Day. Ambition without numbers is not yet investable.

Market Reaction

• Pre-print setup: PG closed at $146.06 on Jan 21, up ~1.9% year-to-date but down 11.3% over the trailing twelve months and 30 days off its highs (52-week closing range $138.04–$176.26). The stock entered the print de-rated and out of favor, with Zacks carrying a Sell rank into the quarter.
• Reaction (Jan 22, before the open): Shares gapped up ~1.4% and closed at $149.93, +2.6% on the day (a $3.87 move), on 18.5M shares versus an 11.1M 30-day average (1.7x). The S&P 500 was up 0.5%, so PG outperformed the tape by roughly two points.

The move is best read as relief, not conviction. Coming into a soft, well-telegraphed quarter with the stock already down double digits over the year and sentiment negative, a two-cent EPS beat plus a maintained core guide and a confident "the trough is behind us" message was enough to clear a low bar. The reaction rewarded the framing and the capital-return durability more than the actual results, which featured flat organic sales and a revenue miss. It is the classic response of a de-rated defensive: the absence of a downgrade to guidance matters more than the quality of the quarter itself.

Street Perspective

Debate: Is the H2 reacceleration real or a comp mirage?

Bull view: The ex-US business is already growing 3%+, the US base-period headwinds are quantified and rolling off, and a stacked innovation calendar (Tide, Olay, baby care) lands in the back half. The setup mechanically improves.

Bear view: Most of the promised H2 lift is just the absence of last year's inventory distortion, layered on flat usage in the US and Europe and a market growing only ~2%. That is stabilization, not reacceleration, and it leaves P&G reliant on share recovery it has not yet demonstrated.

Our take: The bear framing is closer to right on quality. H2 organic almost certainly improves off a flat Q2, but the improvement is comp-aided and modest; the durable question is US share, which management admits is still a work in progress. We would fade the idea that Q3 marks a return to algorithm.

Debate: Is the de-rated valuation an opportunity or a value trap?

Bull view: At ~21x forward core EPS and down ~15% over the year, PG is cheap versus its own history for a Dividend King generating 88% FCF productivity and returning ~$15B annually. Buy the defensive compounder while it is out of favor.

Bear view: ~21x is not cheap for a company delivering 0% organic and flat core EPS; the multiple can compress further toward the high-teens if organic growth does not reaccelerate, and the dividend, while safe, yields under 3%.

Our take: Fairly valued rather than clearly cheap. The downside is cushioned by cash returns and defensiveness, but the re-rating case requires organic growth to inflect, which is precisely what is unproven. That symmetry is why we land at Hold rather than Outperform.

Debate: Does the "reinvention" change the earnings power or is it repackaged BAU?

Bull view: Integrating data, AI, and Supply Chain 3.0 into a closed consumer loop is a genuine structural edge that could lift both growth and productivity, and the heavy investment is already sunk, so incremental returns are high.

Bear view: Much of this is the same integrated-strategy language P&G has used for years, now with an AI vocabulary; without quantified targets it is difficult to underwrite as incremental earnings power.

Our take: Plausible and directionally credible, but not yet underwritable. CAGNY and Investor Day are the catalysts that could convert narrative into numbers; we reserve judgment until management attaches figures to the S-curve.

Model Update Needed

Valuation impact: Trimming FY26 organic and nudging core EPS to the lower half of the guided range supports a fair value in the ~$155–$165 area on ~22–23x a ~$6.90–$7.00 core number, modestly above the current ~$150 spot but not enough to argue for an Outperform. Our framework implies roughly mid-single-digit total return including the ~2.9% dividend, which is in line with, not ahead of, the market.

Thesis Scorecard Post-Earnings

Overall: The defensive and self-funding parts of the thesis are intact and confirmed; the growth engine is stalled and the recovery is asserted rather than demonstrated. On balance the thesis is neutral, with the near-term burden of proof squarely on the second half.

Action: Hold. Initiate coverage at Hold with a fair value in the ~$155–$165 range. We would turn constructive on evidence that US organic sales inflect positive with a volume (not just pricing) component, or on a further de-rating toward the high-teens multiple; we would turn cautious if Q3 organic disappoints against the maintained guide.